Cargando…
Early Complications and Results of Preserflo MicroShunt in the Management of Uncontrolled Open-Angle Glaucoma: A Case Series
We analyze the surgical outcomes and early complications with their management of the Preserflo MicroShunt (Santen Pharmaceutical Co., Ltd., Osaka, Japan) at six-month follow-up. The study is conducted between March 2021 and May 2022. Best-corrected visual acuity (BCVA) logMAR, intraocular pressure...
Autores principales: | Saeed, Emil, Zalewska, Renata, Konopińska, Joanna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315655/ https://www.ncbi.nlm.nih.gov/pubmed/35886531 http://dx.doi.org/10.3390/ijerph19148679 |
Ejemplares similares
-
The PreserFlo MicroShunt in the Context of Minimally Invasive Glaucoma Surgery: A Narrative Review
por: Saeed, Emil, et al.
Publicado: (2023) -
PreserFlo™ MicroShunt Combined with Phacoemulsification versus PreserFlo™ MicroShunt as a Standalone Procedure in Patients with Medically Resistant Open-Angle Glaucoma
por: Fili, Sofia, et al.
Publicado: (2022) -
PreserFlo(®) MicroShunt: An Overview of This Minimally Invasive Device for Open-Angle Glaucoma
por: Gambini, Gloria, et al.
Publicado: (2022) -
PreserFlo MicroShunt® exposure: a case series
por: Bunod, Roxane, et al.
Publicado: (2021) -
XEN(®) Gel Stent compared to PRESERFLO™ MicroShunt implantation for primary open‐angle glaucoma: two‐year results
por: Scheres, Lotte M.J., et al.
Publicado: (2020)